drugset / Trial / NCT05609994
ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and efficacy of a PEPIDH1M vaccine in combination with vorasidenib, a dual inhibitor of mutant IDH1 and IDH2 enzymes, in adult patients diagnosed with recurrent IDH1 mutant lower grade gliomas.
Timeline
- Start
- 2025-07-15
- Primary completion
- 2027-08
- Completion
- 2029-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PEPIDH1M | Peptide | — | Intrathecal |
| Subject | Vorasidenib | Small molecule | 40 mg | Oral |